OverT Bio is developing effective and safe cellular therapies for solid tumors. Founded in 2022 by Dr. Mat Legut and Dr. Neville Sanjana, OverT has pioneered new pooled functional screening and synthetic genomics platforms (OverTarget and OverTCR) to develop next-generation engineered immune cells. OverT is based in New York and has raised $16 million in total funding from investors, including Alexandria Venture Investments, ARTIS Ventures, Cancer Research Institute, Civilization Ventures, Fusion Fund, Gaingels, Hawktail, OMX Ventures and Wing VC.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 05/06/24 | $16,000,000 | Seed |
Alexandria Venture Investments Artis Ventures  Cancer Research Institute. Civilization Ventures Fusion Fund Gaingels Hawktail OMX Ventures Wing Venture Capital | undisclosed |
